Following years of successfully reselling Kwazar Sprayers, Advancing Alternatives assumes the role of Kwazar’s U.S Distributor for its Garden Sprayer Line.

PRESS RELEASE - Following years of successfully reselling Kwazar Sprayers, Advancing Alternatives is assuming the role of Kwazar’s U.S Distributor for its Garden Sprayer Line. A smooth transition is promised from all parties.

Kwazar Corporation is one of the leading plastics processors and manufacturer of sprayers in Poland. Its line of high-quality Garden Sprayers exceed the expectations of gardening professionals and enthusiasts for work in the garden, greenhouse, flowerbeds and household. The garden sprayers have capacities from 0.5l to 15l, are designed for protective and care works, and are designed in accordance with these four principles: Durability, Safety, Comfort, and Innovation.

For over 20 years, Advancing Alternatives has been serving the North American commercial greenhouse and horticulture industries. Its specialties include Touchscreen Environmental Controls, Rack & Pinion Motors, Curtain Motors, Natural Ventilation, and Heating. The company's innovative rolling, thermally sealed, natural ventilation curtain systems and associated products complement any horticultural/agricultural structure. As the needs of growers and farmers have grown and changed, so has Advancing Alternatives. Today, as always, the company's offerings are being developed, expanded, and advanced to new applications so it can be exceedingly responsive to its valued customers.

Select Live Rosin vapes and concentrates offer unrivaled strain-specific flavor and terpene experiences.

WAKEFIELD, Mass., March 10, 2022 /PRNewswire/ -- PRESS RELEASE -- Curaleaf Holdings, Inc., an international provider of consumer products in cannabis, today launched Select Live Rosin, the company's first line of solventless extracts, to patients across Florida. The products will initially launch at 12 Curaleaf locations and will continue to expand statewide by April 7.

Select Live Rosin builds upon the brand's existing collection of premium oil products, including Elite, Elite Live and Essentials, and is formulated for experienced cannabis consumers looking for more flavorful, true-to-flower experiences. The products feature an aromatic, pure cannabis flavor created through the company's live harvesting, flash-freezing and gentle solventless extraction processes that preserve the natural integrity of each strain's terpenes and cannabinoids. Curaleaf's proprietary water-based extraction process eliminates the waste and inefficiencies associated with live rosin manufacturing. This scalable technology allows Curaleaf to offer Select Live Rosin vapes and concentrates at a more accessible price point for patients seeking premium, true-to-flower experiences.

"We are proud to expand our product offerings in Florida to serve our patients' increasingly sophisticated preferences," said Matt Darin, president of Curaleaf US. "Curaleaf's R&D strategy is rooted in delivering novel and exceptional customer experiences, and introducing affordably priced live rosin products along with high-quality vape hardware not only reimagines what is possible for the Company, but for the industry at large."

Select Live Rosin vapes and concentrates will be available in Florida this month and will be followed by Select X Bites in the coming weeks. For more information on product availability, please visit https://selectcannabis.com/find-us.

Kelly's Green plans to be a vertically integrated company with cultivation, extraction and manufacturing capabilities.

JACKSON, Miss., March 10, 2022 – PRESS RELEASE – Kelly G. Williams, an attorney, entrepreneur and mother, has launched Kelly's Green, a medical cannabis company dedicated to providing expertly cultivated medicinal products and patient-centered service to the people of Mississippi.

With the recent passage of the Mississippi Medical Cannabis Act, Williams and the Kelly's Green team are ready to work with providers, caregivers and dispensaries to give pain relief options to patients across the Magnolia state.

"I'm excited today to introduce you to Kelly's Green. We are a patient-centered service medical marijuana company," Williams said. "We're the only company that's been fiercely fighting for Mississippi patients from the very beginning. I made the first financial contribution to Initiative 65, my family and I gathered signatures for a year, and I attended campaign meetings.

“As the only company who's been fighting with Mississippians from the very beginning, Kelly's Green is driven by the same heart and soul, kindness and compassion, humanity and commitment to Mississippians that drove Initiative 65. That service to Mississippians continues with Kelly's Green."

As a woman with business and legal experience, Williams has strong personal ties to both the state of Mississippi and the patients and caregivers who will benefit from medicinal cannabis.

"I've done legal work with thousands of families and children all over the state, and this work has taught me that every human being has inherent worth. Every human being deserves to pursue relief from pain. When my father died from Alzheimer's disease in 2018, I found myself wishing he had more options for treatment and pain relief," Williams said. "Also, when my own niece was diagnosed with Ewing's sarcoma, my eyes were opened to the intensity and senselessness of her pain and suffering. I knew I had to do something to help my niece and other patients like her obtain the pain relief they deserve."

Williams added, "We're opening doors and bringing comfort to communities that haven't yet had this option. Kelly's Green didn't sit on the sidelines and wait until Mississippi had a medical marijuana program. We've been in this fight since the beginning, and we've got the passion, experience and vision to be the very best for medical marijuana in the Hospitality State."

To learn more about Kelly's Green, visit https://kellysgreen.news

The deal expands the company’s footprint to include seven cultivation facilities and 25 retail locations with operations in five states and Canada.

TORONTO, March 9, 2022 – PRESS RELEASE – TerrAscend Corp., a North American cannabis operator, and Gage Growth Corp., a cannabis brand and operator in Michigan, announced they intend to close the previously announced acquisition of Gage by TerrAscend by way of a court-approved plan of arrangement under the Canada Business Corporations Act (the "transaction") on March 10, 2022, subject to satisfaction or waiver of all remaining closing conditions.

Upon completion of the transaction, TerrAscend will have an expanded footprint with owned and managed operations in California, Michigan, Maryland, New Jersey, Pennsylvania, and Canada, including seven cultivation and processing facilities and 25 operating dispensaries serving medical and adult-use cannabis markets in the U.S. and Canada.

"This is a defining moment for TerrAscend as we combine two leading vertically integrated operators with proven cultivation and manufacturing expertise, deep portfolios of proprietary flower strains, and top-selling brands across our core markets," said Jason Wild, executive chairman of TerrAscend. "I look forward to working with the talented Gage team as we integrate and align our cultivation, retail, and operational practices to continue providing our patients and customers with best-in-class product offerings and retail experiences."

"We are thrilled to join forces with TerrAscend to create one of North America's most prominent cannabis companies," Gage CEO Fabian Monaco said. "With our shared core philosophies and complementary areas of expertise, we can't wait to execute on our collective vision."

Key Transaction Highlights and Benefits

The transaction is anticipated to result in the following benefits:

It is expected that the Gage shares will be halted after closing and the Canadian Securities Exchange will delist the Gage shares upon completion of the transaction.

Pennsylvania-based Groff North America brings private-sector cannabis to the U.S. market for scientific study under DEA approval.

Federally legal cannabis is on the U.S. market for scientific research.

As one of a handful of companies to receive approval via memorandums of agreement (MOA) from the U.S. Drug Enforcement Administration (DEA) last year, Pennsylvania-based Groff North America began selling its legal cannabis last month for medical and scientific purposes.

New Mexico-based Bright Green Corp., Arizona-based Scottsdale Research Institute and California-based Biopharmaceutical Research Co. also were recipients of an MOA from the DEA.

Through DEA approval, Groff NA has acquired Schedule I registrations that allow the company to cultivate, extract and process federally legal cannabis in bulk manufacturing; produce precise dosed forms for clinical trials in FDA-approved drugs; import cannabis flower, genetics and extracts from anywhere in the world; and export cannabis flower and cannabis preparations to any of 150-plus signatory counties in the U.N.’s Single Convention on Narcotics.

In addition, the company can conduct its own research and analytical lab testing.

Dr. Steve Groff, the company’s founder and chairman, recently told Pittsburgh NPR that the DEA’s approval will unleash the American scientific community for cannabis research and development. 

“For the first time, real-world marijuana will be available to researchers throughout the country,” he said. “We’re working with some of the top institutions in America in providing new types of material that heretofore wasn’t available from Mississippi.”

Previously, since 1968, researchers had been restricted to accessing government-approved cannabis from one place: the University of Mississippi’s Research Institute of Pharmaceutical Sciences (RIPS). The federally funded program provided products to researchers through the National Institute of Drug Abuse for more than 50 years.

But as Cannabis Conference 2021 keynote speaker Dr. Sue Sisley pointed out in her session this past August in Las Vegas, the quality of government-funded cannabis was anything but representative of what’s available in the private sector. (The University of Mississippi recently launched its own nongovernment-funded cannabis research program).

A medical cannabis researcher and president of the Scottsdale Research Institute, Sisley has made cutting-edge discoveries for pain management and post-traumatic stress disorder, as well as a substitution therapy for opioids. But one barrier to her research was access to quality products.

Through her fight to grow her own cannabis for research, Sisley and two lawyers took on the DEA and Department of Justice through three federal lawsuits. They succeeded in securing a DEA Schedule I bulk manufacturer license—eliminating the 52-year government enforced research monopoly. The license paved way to cultivate cannabis flower for Food and Drug Administration-approved clinical trials.

Trailblazing that path, Sisley’s fight has led to the DEA now loosening its policies for others.

However, following its first federally sanctioned harvest, Groff NA was required to turn its crop over to the DEA before buying it back and selling it, NPR reported. That transfer happened Feb. 2.

While there are compliance costs associated with the DEA Schedule I registrations, Groff told NPR the new opportunities show promise.

“We see a number of opportunities to provide revenue, and then ultimately our long-term play is to be a pharmaceutical manufacturer of a number of cannabis-based drugs,” he said.

Groff NA already has roughly 10 business partners, ranging from larger universities to chemical companies, and expects that number to grow significantly

Cannabis Business Times’ interactive legislative map is another tool to help cultivators quickly navigate state cannabis laws and find news relevant to their markets. View More